
# Danish co-legislation model for disclosure

Carsten Blaesberg, Chief Consultant, The Danish Association of the Pharmaceutical Industry (Lif)



## • Full disclosure takes shape in Denmark

- The Danish Minister of Health and Prevention Astrid Kragh established a working group in beginning of 2012 on the future regulation and disclosure of the relations between industry and HCPs
  - Recommendations for new legislation presented by the working in June 2013

- PAYERS: The Danish national authorities and the Danish Regions
- INDUSTRY: Lif and the MedTech industry

W.G.

Who?

What?

- HCPs: Medical societies, the Danish Medical Association and the Danish Pharmaceutical Association
- POs: Patient and consumer organisations

- Rules of financial advantages and competence
- Inclusion of the MedTech Industry
- Authority-based approval scheme/system
- Disclosure common platform










# Reform of legislation complies with the working group's recommendations



## **Value of co-legislation model and platform**

Establish common platform for disclosure

Reach out to our stakeholders – credible partners

**Common commitment for transparency** 

Common commitment to "stand up for the value of collaboration"



## Key advantages of the Danish model

Key reporting obligation imposed on HCP

Limited administrative burdens imposed on industry

No data privacy issue – no need for consent – all data de-facto individual disclosed

Inclusion of MedTech industry under same regulation

Inclusion of EFPIA's decision on disclosure

Avoid two parallel systems and unnecessary bureaucracy which create no add-on value

## Common Danish platform for disclosure

Collaboration must either be registered or pre- approved by the Danish Health and Medicines Authority

Data reported by HCPs (obligation) – amounts included What: Fees for services, and sponsorships for events (abroad) + shares/owner -ships

The industry provides the authorities with an annual list of their collaborators Full public disclosure (pre- and ongoing) of individual data on the Danish Health and Medicines Authority's website

## What

Fees for research (e.g. clinical research)

Fees for education/speakers

Fees for consultancy (e.g. advisory boards)

Fees for market research

Events - Sponsorships and companies

Donations and grants to hospitals

Shares

Ownership/Board of Directors

# How

Registration & disclosure of individual data

Registration & disclosure of individual data

Pre-approval & disclosure of individual data

Pre-approval & disclosure of individual data

Registration of events held abroad. Individual disclosure (no amounts so far for events)

Lif has a disclosure code

Registration & disclosure of individual data Pre-approval if amount exceeds EUR 30,000


Pre-approval & disclosure



#### Status and timeline

Legislation will be adopted at the end of May (consensus in Parliament)

Executive Orders and guidelines are established Task force with stakeholders is set up (for 3 years) The Act will become effective from November 1 2014





### Collaboration continues with our stakeholders

- Common information leaflet
- Joint public debate meetings
- Who: Lif, the MedTech industry, the Danish Generic Medicines Industry Association, the Danish Medical Association, the Medical Societies, the Danish Pharmaceutical Association, the Dentists Association and the Danish Nurses' Organisation.

